12-Bromododecanoic Acid

Identification

Generic Name
12-Bromododecanoic Acid
DrugBank Accession Number
DB02405
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 279.214
Monoisotopic: 278.088142627
Chemical Formula
C12H23BrO2
Synonyms
Not Available

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UGlycodelinNot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as medium-chain fatty acids. These are fatty acids with an aliphatic tail that contains between 4 and 12 carbon atoms.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Fatty Acyls
Sub Class
Fatty acids and conjugates
Direct Parent
Medium-chain fatty acids
Alternative Parents
Halogenated fatty acids / Straight chain fatty acids / Monocarboxylic acids and derivatives / Carboxylic acids / Organobromides / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds / Alkyl bromides
Substituents
Aliphatic acyclic compound / Alkyl bromide / Alkyl halide / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Halogenated fatty acid / Hydrocarbon derivative / Medium-chain fatty acid / Monocarboxylic acid or derivatives
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
bromo fatty acid (CHEBI:49519) / Halogenated fatty acids (LMFA01090007)
Affected organisms
Not Available

Chemical Identifiers

UNII
RP072ZQ00E
CAS number
73367-80-3
InChI Key
YYKBWYBUCFHYPR-UHFFFAOYSA-N
InChI
InChI=1S/C12H23BrO2/c13-11-9-7-5-3-1-2-4-6-8-10-12(14)15/h1-11H2,(H,14,15)
IUPAC Name
12-bromododecanoic acid
SMILES
OC(=O)CCCCCCCCCCCBr

References

General References
Not Available
PubChem Compound
175468
PubChem Substance
46506537
ChemSpider
152887
ChEBI
49519
ChEMBL
CHEMBL1231458
ZINC
ZINC000001637721
PDBe Ligand
BRC
PDB Entries
1bso

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00138 mg/mLALOGPS
logP5.56ALOGPS
logP4.58Chemaxon
logS-5.3ALOGPS
pKa (Strongest Acidic)4.95Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area37.3 Å2Chemaxon
Rotatable Bond Count11Chemaxon
Refractivity66.64 m3·mol-1Chemaxon
Polarizability29.3 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9815
Blood Brain Barrier+0.9288
Caco-2 permeable+0.5795
P-glycoprotein substrateNon-substrate0.8197
P-glycoprotein inhibitor INon-inhibitor0.9732
P-glycoprotein inhibitor IINon-inhibitor0.931
Renal organic cation transporterNon-inhibitor0.883
CYP450 2C9 substrateNon-substrate0.8229
CYP450 2D6 substrateNon-substrate0.8731
CYP450 3A4 substrateNon-substrate0.722
CYP450 1A2 substrateNon-inhibitor0.7109
CYP450 2C9 inhibitorNon-inhibitor0.8432
CYP450 2D6 inhibitorNon-inhibitor0.9571
CYP450 2C19 inhibitorNon-inhibitor0.9551
CYP450 3A4 inhibitorNon-inhibitor0.9354
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9836
Ames testAMES toxic0.9106
CarcinogenicityNon-carcinogens0.6788
BiodegradationReady biodegradable0.6132
Rat acute toxicity2.0357 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9339
hERG inhibition (predictor II)Non-inhibitor0.945
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-01u0-7690000000-22900b8bbaa7f006d0cc
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-2090000000-e02d47d1c6f6f9b1d7dc
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-9010000000-539d14eea570f105558e
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a5a-9100000000-1096aa2ada314652b65c
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-9000000000-455789f590db072f4f93
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0apl-9000000000-682e42b7a03bcc351dab
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-153.79912
predicted
DeepCCS 1.0 (2019)
[M+H]+156.50726
predicted
DeepCCS 1.0 (2019)
[M+Na]+164.31717
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Small molecule binding
Specific Function
This protein is, quantitatively, the main protein synthesized and secreted in the endometrium from mid-luteal phase of the menstrual cycle and during the first semester of pregnancy.
Gene Name
PAEP
Uniprot ID
P09466
Uniprot Name
Glycodelin
Molecular Weight
20624.015 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]

Drug created at June 13, 2005 13:24 / Updated at July 02, 2020 13:16